Perioperative Toripalimab and Endostatin for Stage II Melanoma
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs, toripalimab (an immunotherapy) and endostatin (which targets blood vessels), given before and after surgery for stage II melanoma. The goal is to see if this combination helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your melanoma is stage II and started on the skin or on the palm/sole (not in the eye or a mucus membrane).
- You have not had any prior treatment for your melanoma.
- You are able to walk and care for yourself (ECOG score 0-1).
- Your blood counts, liver and kidney function, and heart function are within certain limits.
- You are willing to use birth control during the study and for 6 months after.
- You have no history of autoimmune disease or serious bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (iparomlimab, tuvoraleimab, bevacizumab, and chemotherapy) as a first or second treatment for advanced acral or mucosal melanoma. It aims to see if this mix can help shrink or control the cancer.
This trial tests two medicines given before surgery to shrink stage III–IV acral melanoma (a melanoma type on the hands/feet) and improve outcomes. If the tumors respond, surgery can happen afterward as planned.
This trial tests a combination of two drugs—an oral chemotherapy (topotecan) and an immunotherapy (toripalimab)—for advanced or recurrent endometrial cancer that has not responded to first-line treatment. The goal is to see if this combination can help control the cancer.
This trial studies whether adding toripalimab (an immunotherapy medicine) to radiation can improve outcomes for people with operable stage II to IIIA non-small cell lung cancer. It’s designed for cancers that can be fully removed with surgery, and it aims to see if this combination helps more than radiation alone/standard care.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
This trial tests a combination of three medicines (pucotenlimab, lenvatinib, and temozolomide) given before surgery to shrink stage IIB or III acral melanoma. The goal is to see if this treatment can improve outcomes for people whose melanoma can be removed by surgery.
Hear when a new Acral Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.